RASEGLURANT

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H13FN2
Molecular Weight	240.2755
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC(C#CC2=CC(F)=CC=C2)=C(N)C(C)=C1

InChI

InChIKey=MEDCLNYIYBERKO-UHFFFAOYSA-N

InChI=1S/C15H13FN2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9H,17H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C15H13FN2
Molecular Weight	240.2755
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800023360 | https://www.ncbi.nlm.nih.gov/pubmed/20218930 | https://www.biospace.com/article/addex-pharmaceuticals-adx10059-has-potential-for-parkinson-s-disease-levodopa-induced-dyskinesia-pd-lid-

ADX 10059 is a first-in-class reflux inhibitor that works by reducing activation of the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM). This approach may lead to a new class of drugs that addresses the causes of GERD rather than just the symptoms. ADX 10059 is a potent selective NAM of the mGluR5, with an IC50 of 17.1 nM on hmGluR5 showing good selectivity compared with > 65 other receptors, transporters, ion channels and enzymes. ADX 10059 completed Phase IIb testing in gastroesophageal reflux disease (GERD) and migraine prevention, demonstrated significant potential in a non-human primate model of Parkinson's disease levodopa induced dyskinesia (PD-LID). However, Addex Pharmaceuticals announced the discontinuation of development of ADX 10059 in December 2009 due to liver enzyme changes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Metabotropic glutamate receptor 5 40 Target ID: CHEMBL3227 Sources: https://gut.bmj.com/content/58/9/1192	Negative Allosteric Modulator 43		17.1 nM [IC50]
Metabotropic glutamate receptor 5 40 Target ID: CHEMBL3227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19460767	Negative Allosteric Modulator 43		17.1 nM [IC50]

PubMed

Title	Date	PubMed
Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?	2010-04	20218930
Gateways to clinical trials.	2009-12	20140276

Patents

Sample Use Guides

In Vivo Use Guide

ADX 10059 120 mg twice-daily given for two weeks was well tolerated and the tolerability profile seen is compatible with use in the treatment of GERD.

Route of Administration: Oral

In Vitro Use Guide

ADX 10059 is a potent selective NAM of the mGluR5, with an IC50 of 17.1 nM on hmGluR5 showing good selectivity compared with > 65 other receptors, transporters, ion channels and enzymes

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:36:11 GMT 2025` Edited by `admin` on `Mon Mar 31 18:36:11 GMT 2025`
Record UNII	66UCJ8Z8L1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ADX-10059

Preferred Name

English

RASEGLURANT

Official Name

English

Raseglurant [WHO-DD]

Common Name

English

ADX10059

Code

English

3-PYRIDINAMINE, 2-(2-(3-FLUOROPHENYL)ETHYNYL)-4,6-DIMETHYL-

Systematic Name

English

raseglurant [INN]

Common Name

English

2-(2-(3-FLUOROPHENYL)ETHYNYL)-4,6-DIMETHYLPYRIDIN-3-AMINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C241